Evidence map›Paper›PMID 15881651›Full record

ArticleMolecular and cellular biochemistry2005

Protein synthesis and urokinase mRNA metabolism.

Sreerama Shetty

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Sreerama ShettyDepartment of Specialty Care Services, The University of Texas Health Center at Tyler, 11937 U.S. Highway 271, Tyler, TX 75708, USA. sreerama.shetty@uthct.edu
The University of Texas Health Science Center at Tyler · US

Funding

Regulation of Lung Epithelial Fibrinolysis by UrokinaseR01HL071147 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SHETTY, SREERAMA · 2002 to 2005
$1.0M
CONTROL OF FIBRINOLYTIC PATHWAYS IN LUNG DISEASER01HL062453 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SHETTY, SREERAMA · 1999 to 2004
$751k
NHLBI NIH HHS HL 62453NHLBI NIH HHS HL 71147
6 · The paper itself

Abstract

Expression of the urokinase-type plasminogen activator (uPA) is under tight regulation by hormones, cytokines and growth factors under physiological conditions. Treatment of lung epithelial (Beas2B) cells with translation inhibitors induces uPA mRNA expression, as well as early response genes. To understand the specific expression and regulation of uPA mRNA, we treated Beas2B cells with cycloheximide (CycD), anisomycin, emitine and puromycin in a time-dependent manner and measured uPA mRNA expression by Northern blotting. All these agents induced uPA mRNA by two- to seven-fold within 3 h after treatment in Beas2B cells. CycD, emitine, puromycin and anisomycin also enhanced uPA mRNA half-life by three- to five-fold in Beas2B cells treated with DRB, an inhibitor of transcription. However, run-on-transcription experiments indicated that these agents failed to induce uPA mRNA transcription indicating that they augment uPA mRNA mainly due to increased stability. Using gel mobility shift, we identified an uPA mRNA binding protein (uPA mRNABp) that selectively binds to uPA mRNA [Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG: The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93: 1380-1387, 1994]. Binding of both cytoplasmic and nuclear uPA mRNABp to uPA mRNA was abolished after treatment with translation inhibitors, which coincides with the maximal expression of uPA mRNA. We also found a similar decline in HuR and heterogeneous nuclear ribonucleoprotein C (hnRNPC) which are known to stabilize uPA mRNA both in the nuclear and cytosolic compartments. These results strongly suggest that increased uPA mRNA stability induced by translational inhibitors involves the interaction of uPA mRNA with a degrading protein factor rather than increased interaction of proteins that are known to stabilize uPA mRNA. These data also strongly suggests that down-regulation of the uPA-uPA mRNABp interaction by translational inhibitors rather than the translocation of uPA mRNABp contributes to increased uPA mRNA stability. This pathway may regulate uPA-mediated functions of the lung epithelium in the context of inflammation or neoplasia.

Indexed as

Antigens, SurfaceBronchiCells, CulturedCycloheximideELAV-Like Protein 1ELAV ProteinsEpithelial CellsHeterogeneous-Nuclear Ribonucleoprotein Group CHumansNucleic Acid Synthesis InhibitorsProtein BiosynthesisProtein Synthesis InhibitorsRNA-Binding ProteinsRNA, MessengerRNA Processing, Post-TranscriptionalRNA StabilityAntigens, SurfaceCycloheximideELAVL1 protein, humanELAV-Like Protein 1ELAV ProteinsHeterogeneous-Nuclear Ribonucleoprotein Group CNucleic Acid Synthesis InhibitorsProtein Synthesis InhibitorsRNA-Binding ProteinsRNA, MessengerUrokinase-Type Plasminogen Activator

Identifiers

PMID15881651
OpenAlexW1973131663

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.